Initial results from a phase I/II dose escalation and expansion trial studying tebotelimab, a PD-1/LAG-3 bispecific antibody in advanced HCC patients who had failed prior immunotherapy, revealed that tebotelimab had a tolerable safety profile [140,141,142]. Here, LAG3 is linked to hepatocellular carcinoma.